These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15482535)

  • 21. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
    Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
    Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
    van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
    Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
    Wang CC; Liu CJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety in chronic hepatitis B adolescent patients with lamivudine therapy].
    Lu WL; Xie DY; Yao JL; Yao GB; Cui ZY; Zhang DF; Wu L
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):429-31. PubMed ID: 15268810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
    J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
    Alexander G; Baba CS; Chetri K; Negi TS; Choudhuri G
    BMC Gastroenterol; 2005 Sep; 5():29. PubMed ID: 16164746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
    Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
    Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamivudine therapy for children with chronic hepatitis B.
    Liberek A; Szaflarska-Popławska A; Korzon M; Łuczak G; Góra-Gebka M; Łoś-Rycharska E; Bako W; Czerwionka-Szaflarska M
    World J Gastroenterol; 2006 Apr; 12(15):2412-6. PubMed ID: 16688835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
    N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
    Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
    Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
    Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
    Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.
    Rizzetto M; Tassopoulos NC; Goldin RD; Esteban R; Santantonio T; Heathcote EJ; Lagget M; Taak NK; Woessner MA; Gardner SD
    J Hepatol; 2005 Feb; 42(2):173-9. PubMed ID: 15664241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection.
    Kawaoka T; Suzuki F; Akuta N; Suzuki Y; Arase Y; Sezaki H; Kawamura Y; Hosaka T; Kobayashi M; Ikeda K; Kumada H
    J Gastroenterol; 2007 May; 42(5):395-401. PubMed ID: 17530365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.
    Da Silva LC; Pinho JR; Sitnik R; Da Fonseca LE; Carrilho FJ
    J Gastroenterol; 2001 Jul; 36(7):476-85. PubMed ID: 11480792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
    Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
    Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HBV resistant to lamivudine: experimental and clinical studies.
    Zhou DY; Cao YJ; Lin LY; Wang H; Huang JS
    Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):519-22. PubMed ID: 14607678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.